Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24967801 | 0.86 | NPC1 (0.36) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18806118 | 0.80 | NPC1 (0.39) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24967785 | 0.78 | GRM5 (0.44) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19678264 | 0.78 | SMN1; SMN2 (0.53) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21789412 | 0.77 | NPC1 (0.39) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23502135 | 0.75 | NPC1 (0.35) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25097588 | 0.75 | KDM4E (0.56) | LMNAKDM4ERAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21752181 | 0.75 | TDP1 (0.51) | KDM4ERAB9ASMN1; SMN2ALDH1A1RECQL | |
| SCHEMBL23613496 | 0.72 | BRAF (0.36) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25097587 | 0.72 | RAB9A (0.46) | KDM4ENPC1RAB9ARECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | LMNA 1541/4885KDM4E 4475/4885NPC1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.